FibroGen (NASDAQ:FGEN) Receives “Buy” Rating from HC Wainwright
HC Wainwright reiterated their buy rating on shares of FibroGen (NASDAQ:FGEN – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on shares of FibroGen in a research report on Friday, March 14th. They set a “hold” rating on […]
HC Wainwright reiterated their buy rating on shares of FibroGen (NASDAQ:FGEN – Free Report) in a report published on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. Separately, StockNews.com initiated coverage on shares of FibroGen in a research report on Friday, March 14th. They set a “hold” rating on […]
